Randomized Trialhigh evidence
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
JAMA·May 19, 2026·PMID 42018318
Why it mattersThis is the first randomized evidence that an epigenetic agent improves outcomes in high-risk DLBCL, specifically targeting the poor-prognosis double-expressor subgroup where standard R-CHOP often fails.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled